The aim of including IL-2 together with aMUC1aCD3 in TILT-322 is to generate anti-tumor immune responses by accelerating effector CD8+ T and helper CD4+ T cell proliferation in Mucin1 (MUC1)-positive tumors. Here, IL2 is linked to neoplasm.